Panel Rejects “Relative Contraindication” Labeling For WorldHeart’s LVAS
This article was originally published in The Gray Sheet
Executive Summary
The population that would be covered by a proposed expanded indication for WorldHeart's Novacor left-ventricular assist system is poorly defined by the retrospective study submitted by the firm, an FDA advisory panel concludes